Celldex has added another round of positive data demonstrating that its brain cancer vaccine rindopepimut--more formally called Rintega and less formally "rindo"--provided a clear though relatively modest average survival benefit for recurrent glioblastoma patients in a Phase II study. And with the initial data set from Phase III looming later in the year, the biotech is carefully moving forward with its ongoing dialogue with regulators to gauge just how receptive they may be to speeding up an approval.
I've tried to capture some of the most interesting responses we've gotten over the past few days since we published our 2012 report.
Celldex Therapeutics ($CLDX) has unveiled overall survival data from a 65-person Phase II trial of the company's brain cancer vaccine rindopepimut. In the single-arm trial, the Needham, MA-based
Biotech stocks were rocked last week when Dendreon, which makes the only approved cancer vaccine, reported that sales of Provenge significantly missed their mark. Dendreon lost two-thirds of its